Semax (5mg & 10mg)

Semax (10mg): A Synthetic Nootropic and Neuroprotective Heptapeptide — an Analogue of Adrenocorticotropic Hormone Fragment 4-7 (ACTH 4-7, Met-Glu-His-Phe) with the C-Terminal Pro-Gly-Pro Extension, Sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), Designed to Provide Nootropic (Cognitive-Enhancing), Neuroprotective, Stimulant-Like, and Adaptogenic Effects with a Favorable Safety Profile and Low Abuse Potential — the 10mg Vial Format for Investigational Research in Cognitive Enhancement, Neuroprotection, Stroke Recovery, ADHD, Chronic Fatigue, and Neuropsychopharmacology

Semax is a synthetic nootropic and neuroprotective heptapeptide (7 amino acids) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) — it is an analogue of the adrenocorticotropic hormone (ACTH) fragment 4-7 (Met-Glu-His-Phe, MEHF), which is a naturally occurring peptide fragment derived from ACTH (a pituitary hormone best known for stimulating cortisol release from the adrenal glands, but which also has significant central nervous system effects on cognition, attention, motivation, and memory). Semax was developed by Russian researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s-1990s (the same research group that developed Selank), as part of a research program to develop peptide-based nootropic (cognitive-enhancing) and neuroprotective drugs based on ACTH fragments. Semax was designed by extending the ACTH 4-7 tetrapeptide sequence (Met-Glu-His-Phe) with a C-terminal tripeptide extension (Pro-Gly-Pro, PGP) — this extension was chosen for several key reasons: (1) Metabolic stability — the Pro-Gly-Pro motif confers significant resistance to degradation by peptidases (exopeptidases and endopeptidases), dramatically extending the peptide's half-life compared to the rapidly degraded ACTH 4-7 fragment (which has a half-life of only minutes); (2) Blood-brain barrier (BBB) penetration — the Pro-Gly-Pro motif has been shown to enhance the transport of peptides across the blood-brain barrier, which is critical for Semax's central nervous system effects (cognition, neuroprotection); (3) Pharmacological modulation — the Pro-Gly-Pro extension modulates the peptide's pharmacological profile, enhancing its nootropic and neuroprotective effects while eliminating the endocrine (cortisol-releasing) effects of full-length ACTH (Semax does NOT stimulate cortisol release or have significant endocrine effects, unlike full ACTH); (4) Structural homology with Selank — it is notable that the related peptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP), developed by the same research group, also has the C-terminal Pro-Gly-Pro extension (in Selank's case, extending the tuftsin tetrapeptide [Thr-Lys-Pro-Arg] with Pro-Gly-Pro); this Pro-Gly-Pro extension is a deliberate design motif used by this research group to create stabilized, BBB-penetrating peptide analogues with enhanced pharmacological profiles. Semax has been extensively studied in preclinical and clinical research in Russia and Eastern Europe, where it has been approved as a pharmaceutical drug (under the brand name Semax) for various indications including: recovery from ischemic stroke (cerebrovascular accident), cognitive and memory impairments (including vascular encephalopathy, post-stroke cognitive decline, and age-related cognitive impairment), attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, increased mental and physical performance under stress and fatigue, and optic nerve atrophy (as a neuroprotective agent). It is also used off-label for: general cognitive enhancement and nootropic use (focus, memory, learning, productivity), neuroprotection (prevention of cognitive decline, brain health), treatment-resistant depression (as an adjunct), chronic fatigue syndrome, jet lag and shift work disorder, anxiety (at lower doses — though at higher doses it can be stimulant-like and may increase anxiety), recovery from traumatic brain injury, and enhancement of athletic/mental performance. Outside of Russia/Eastern Europe, Semax is primarily available as a research-grade peptide/investigational compound for laboratory and preclinical research, and it is not FDA-approved in the United States or approved by the EMA in Europe for any indication (though it is being studied in clinical trials and is available as a research chemical). Semax exerts its biological effects through several interconnected mechanisms: (1) Nootropic/cognitive-enhancing effects via multiple neurotransmitter systems — Semax modulates the levels and turnover of key neurotransmitters including dopamine, serotonin, norepinephrine, acetylcholine, and glutamate in brain regions involved in cognition, attention, motivation, and memory (prefrontal cortex, hippocampus, striatum, nucleus accumbens); it particularly enhances dopaminergic and noradrenergic neurotransmission in the prefrontal cortex (critical for executive function, attention, working memory, and motivation), which contributes to its stimulant-like, focus-enhancing, and motivation-enhancing effects; (2) Neurotrophic factor expression and neuroplasticity — Semax increases the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the brain, particularly in the hippocampus and prefrontal cortex; these neurotrophic factors promote neuronal survival, differentiation, synaptic plasticity, long-term potentiation (LTP — the cellular basis of learning and memory), and neurogenesis (formation of new neurons in the hippocampal dentate gyrus); Semax also increases the expression of neurotrophin receptors (TrkA, TrkB) and enhances their signaling; (3) Neuroprotective effects — Semax has demonstrated potent neuroprotective effects in preclinical models of cerebral ischemia/stroke, traumatic brain injury, hypoxia, excitotoxicity, oxidative stress, and neurodegenerative diseases; mechanisms include: reduction of oxidative stress and reactive oxygen species (ROS), inhibition of pro-inflammatory cytokine production and neuroinflammation (microglial activation), inhibition of neuronal apoptosis (programmed cell death), enhancement of cerebral blood flow and microcirculation, improvement of mitochondrial function and energy metabolism, stabilization of cell membranes, and promotion of neurotrophic factor expression and neuronal survival; (4) Antioxidant effects — Semax reduces oxidative stress, enhances endogenous antioxidant defenses (superoxide dismutase, catalase, glutathione), and reduces lipid peroxidation; (5) Anti-inflammatory and immunomodulatory effects — Semax modulates immune function and reduces inflammation, particularly neuroinflammation (which is increasingly recognized as a contributor to cognitive decline, depression, and neurodegenerative diseases); (6) Adaptogenic and stress-protective effects — Semax enhances the body's ability to cope with physical and mental stress, reduces stress-induced cognitive impairment and fatigue, and improves performance under stressful conditions; it modulates the hypothalamic-pituitary-adrenal (HPA) axis and stress hormone responses (though it does NOT have the cortisol-releasing effects of full ACTH); (7) Metabolic and vascular effects — Semax improves cerebral blood flow and microcirculation, enhances glucose utilization and energy metabolism in the brain, and may have beneficial effects on vascular function; (8) Gene expression modulation — Semax modulates the expression of numerous genes involved in neurotransmission, neuroplasticity, inflammation, stress response, cell survival, and metabolism, through effects on transcription factors (CREB, NF-κB, AP-1) and epigenetic mechanisms. Semax is typically administered by intranasal (IN) application (the most common route, particularly in its pharmaceutical form in Russia — as nasal drops or spray, which provides rapid absorption and direct nose-to-brain delivery via the olfactory and trigeminal pathways) or by subcutaneous (SC) injection (common in research settings); it is NOT orally active (as a peptide, it is degraded by gastrointestinal proteases and has poor oral bioavailability). The 10mg vial format of Semax provides a convenient quantity for research use. Semax is widely regarded as having a favorable safety profile — in preclinical and clinical studies, Semax has been shown to be well-tolerated, with minimal side effects, no significant toxicity (even at high doses), no significant endocrine effects (unlike full ACTH — Semax does not stimulate cortisol release), no dependence or withdrawal effects, low abuse potential (it is not a controlled substance, though it has mild stimulant-like effects that could theoretically be misused), and no significant drug-drug interactions (it does not significantly inhibit or induce cytochrome P450 enzymes). Common side effects (usually mild and transient) may include: mild headache, mild nausea (especially at higher doses), mild anxiety, restlessness, or jitteriness (at higher doses — due to stimulant-like effects), insomnia or sleep disturbance (if administered too late in the day — due to stimulant-like effects), mild fatigue or drowsiness (paradoxically, in some individuals at lower doses or after the stimulant effects wear off), mild dizziness, irritability or mood changes (at high doses), increased heart rate or blood pressure (mild, at high doses — due to stimulant/noradrenergic effects), appetite suppression (mild, at high doses), injection site reactions (with SC administration), and mild nasal irritation (with intranasal administration). Contraindications include: known hypersensitivity to Semax or any of its components, pregnancy and breastfeeding (insufficient safety data), severe cardiovascular disease (use caution — particularly uncontrolled hypertension, arrhythmias, recent MI/stroke), severe anxiety disorders, panic disorder, or hyperthyroidism (Semax's stimulant-like effects could worsen these conditions), seizure disorders or epilepsy (use caution — though no pro-convulsant effects demonstrated, stimulant effects could theoretically lower seizure threshold in susceptible individuals), bipolar disorder (could theoretically trigger mania/hypomania at high doses — use caution, monitor mood), history of substance abuse (mild stimulant-like effects could theoretically be misused — use with appropriate oversight), and children (unless specifically prescribed for ADHD under medical supervision — Semax is approved for ADHD in children in Russia). As of 2026, Semax is NOT FDA-approved in the United States for any indication — it is a research-grade/investigational compound in the US and most Western countries, though it is approved as a pharmaceutical drug in Russia and some Eastern European countries. The research-grade Semax supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Practical Research Guide for Semax (10mg Vial): Reconstitution, Dosing, Administration Routes, Cycling, and Combination Strategies

• Reconstitution of the 10mg vial: Semax is supplied as a lyophilized (freeze-dried) powder in a 10mg vial and must be reconstituted before use. Materials needed: Semax 10mg vial, bacteriostatic water (preferred for multi-dose intranasal or SC use — contains 0.9% benzyl alcohol as preservative) or sterile water (for single-dose use), alcohol swabs, 1mL or 3mL syringe with needle (for reconstitution and SC injection), or a nasal spray bottle/dropper (for intranasal administration). Procedure: (1) Wipe the vial stopper with an alcohol swab and allow to dry; (2) Draw up the desired volume of bacteriostatic/sterile water; (3) Inject the water into the Semax vial, directing the stream down the side to minimize foaming; (4) Gently swirl or roll the vial to dissolve (do NOT shake vigorously — can cause foaming and peptide denaturation); (5) Allow foam to dissipate (1-5 minutes); (6) The solution should be clear, colorless, and free of particulates — if cloudy, discolored, or particulate, do not use. Reconstitution volumes and concentrations: (a) Add 1mL → 10mg/mL (10,000 mcg/mL) — concentrated, suitable for adding to a larger intranasal spray base or for high-dose SC use; 1mg = 0.1mL, 500mcg = 0.05mL, 250mcg = 0.025mL; (b) Add 2mL → 5mg/mL (5,000 mcg/mL) — moderate concentration; 1mg = 0.2mL, 500mcg = 0.1mL, 250mcg = 0.05mL; (c) Add 5mL → 2mg/mL (2,000 mcg/mL) — RECOMMENDED for most intranasal and SC use, good balance of concentration and ease of dosing; 1mg = 0.5mL, 500mcg = 0.25mL, 250mcg = 0.125mL; (d) Add 10mL → 1mg/mL (1,000 mcg/mL) — dilute, easy to measure small intranasal doses accurately; 1mg = 1.0mL, 500mcg = 0.5mL, 250mcg = 0.25mL. For intranasal administration, a common approach is to reconstitute with 2-5mL and then transfer to a nasal spray bottle (which may further dilute with saline or a suitable nasal spray base to achieve a convenient spray volume — e.g., a typical nasal spray delivers ~0.1mL per spray, so a 2mg/mL solution delivers ~200mcg per spray). A 10mg vial reconstituted with 5mL (2mg/mL) provides 5mL of solution, enough for: 5 doses of 1mg, 10 doses of 500mcg, 20 doses of 250mcg, etc. (for SC); for intranasal, it depends on spray volume and dose per spray.
• Dosing guidelines (research/empirical, not FDA-approved): Semax dosing varies significantly depending on the administration route, indication, individual response, and whether it is used as monotherapy or in combination. The following are general research/empirical dosing ranges (based on Russian clinical studies and empirical use in the research peptide community): (a) Intranasal (IN) — most common route: (1) Low dose: 100-250 mcg (0.1-0.25mg) per administration, 1-2 times daily — suitable for: mild cognitive enhancement, focus, nootropic use, beginners, sensitive individuals, combination therapy, or for anxiolytic effects (at lower doses, Semax can be calming rather than stimulating); (2) Moderate dose (most common for nootropic use): 250-500 mcg (0.25-0.5mg) per administration, 2-3 times daily (total daily dose 500-1500 mcg / 0.5-1.5mg) — suitable for: general cognitive enhancement, focus, memory, learning, productivity, studying, work performance, mental fatigue; this is the most common research dose range for nootropic use; (3) Higher dose: 500-1000 mcg (0.5-1.0mg) per administration, 2-3 times daily (total daily dose 1-3mg) — suitable for: more pronounced stimulant/nootropic effects, severe mental fatigue, cognitive impairment (post-stroke, vascular encephalopathy, MCI), ADHD (at higher doses, under medical supervision), or individuals who do not respond to lower doses; higher doses increase the risk of stimulant side effects (anxiety, jitteriness, insomnia, increased HR/BP); (4) Maximum/clinical dose: up to 3-6mg total daily (in Russian clinical trials for stroke recovery and severe cognitive impairment, doses up to 6-12mg/day have been used, often via SC injection or IV); these high doses are for clinical use under medical supervision and are not recommended for self-administration due to increased side effect risk. (b) Subcutaneous (SC) injection — common research route: (1) Low dose: 100-500 mcg (0.1-0.5mg) per injection, once daily; (2) Moderate dose (most common): 500-1000 mcg (0.5-1.0mg) per injection, once daily; (3) Higher dose: 1-3mg per injection, once daily; (4) SC dosing is typically once daily (due to longer-lasting effects from injection compared to intranasal), while intranasal is often 2-3 times daily (due to faster absorption but shorter duration per dose); (5) SC administration may produce more sustained and pronounced effects than intranasal (higher bioavailability), but is less convenient and requires injection. (c) Frequency and timing: (1) Intranasal: typically 2-3 times daily, administered in the morning, early afternoon, and (if needed) late afternoon — AVOID administering within 4-6 hours of bedtime (due to stimulant-like effects that can cause insomnia); (2) SC: typically once daily, administered in the morning (or early afternoon at the latest) — avoid evening administration; (3) For best cognitive effects during the day, administer the first dose 15-30 minutes before starting work/study/mental tasks; (4) Some users use Semax on weekdays only (for work/study) and take weekends off, while others use it daily; both approaches are used, and periodic breaks are generally recommended to maintain sensitivity and assess ongoing need. (d) Cycle length: (1) Acute/short-term use: 1-4 weeks — for situational cognitive demands (exam periods, intense work projects), mental fatigue, jet lag, or to assess effects; (2) Standard cycle: 4-8 weeks — for general nootropic use, cognitive enhancement, most common research cycle; (3) Longer cycles: 8-12 weeks or longer — for cognitive impairment, neuroprotection, recovery from stroke/TBI, or chronic conditions (under medical supervision); Semax does not cause significant dependence or tolerance, so it can potentially be used long-term, but periodic breaks (1-2 weeks off after 8-12 weeks) are generally recommended to assess ongoing need, maintain sensitivity, and avoid potential unknown long-term effects; (4) For neuroprotection/brain health, some users use it in cycles (e.g., 1 month on, 1-2 weeks off) throughout the year. (e) Onset and duration: (1) Intranasal onset: ~10-30 minutes (rapid absorption through nasal mucosa, direct nose-to-brain delivery via olfactory/trigeminal pathways); many users report noticing enhanced focus, alertness, and mental clarity within 15-30 minutes of intranasal administration; (2) SC onset: ~30-60 minutes; (3) Duration per dose: intranasal ~4-8 hours (may need redosing 2-3x daily); SC ~8-24 hours (once daily often sufficient); (4) Cumulative effects: while acute cognitive effects are noticed within the first dose, the full nootropic and neuroplastic effects (BDNF increase, synaptic plasticity, neurogenesis) develop over days to weeks of consistent use — many users report that effects improve over the first 1-2 weeks and that benefits (improved memory, learning, mental clarity) may persist for some time after stopping (due to lasting neuroplastic changes). (f) Important dosing principles: (1) Start low and titrate up — always start with a low dose (100-250mcg intranasal, or 250-500mcg SC) to assess individual tolerance (particularly sensitivity to stimulant effects like anxiety, jitteriness, insomnia), then gradually increase over 3-7 days until the desired effect is achieved or side effects appear; (2) Individual variability — response to Semax varies significantly between individuals (genetics, body weight, metabolism, baseline cognitive state, neurotransmitter levels, concurrent medications, tolerance); some people are very sensitive (notice effects at 100mcg), while others may need higher doses; (3) Use the lowest effective dose — once the desired cognitive effect is achieved, use the lowest dose that maintains it (to minimize side effects, cost, and potential unknown long-term effects); higher doses do not necessarily produce better cognitive effects and may instead produce more side effects (anxiety, jitteriness, insomnia, irritability); (4) Be consistent — for best results (particularly for cumulative neuroplastic effects), use Semax consistently (at the same time(s) daily) for at least 2-4 weeks before fully assessing efficacy; intermittent use may produce acute effects but may not achieve the full cumulative benefits; (5) Track effects — keep a journal or log to track: dose, route, time of administration, cognitive performance (subjective ratings of focus, memory, clarity, productivity; or objective tests if desired), mood, energy, sleep quality/quantity, side effects (anxiety, jitteriness, insomnia, headache, nausea, HR/BP), and any other relevant outcomes; this helps determine the optimal dose, route, timing, and cycle length, and objectively assess efficacy; (6) Avoid late-day dosing — due to stimulant-like effects, avoid administering within 4-6 hours of bedtime (for intranasal) or within 8-10 hours of bedtime (for SC, which has longer duration); late-day dosing can cause insomnia, delayed sleep onset, and reduced sleep quality; (7) Be aware of the "stimulant spectrum" — Semax has dose-dependent effects: at LOW doses, it may be calming, anxiolytic, and gently focus-enhancing (some users report it helps with anxiety); at MODERATE doses, it is a balanced nootropic/stimulant (enhanced focus, motivation, mental clarity, energy without excessive jitteriness); at HIGH doses, it becomes more stimulant-like and can cause anxiety, jitteriness, restlessness, irritability, insomnia, increased HR/BP, and a "speedy" feeling; the optimal dose is the one that produces the desired cognitive enhancement without crossing into the unpleasant stimulant side effect range.
• Administration techniques: (a) Intranasal administration technique (most common): Intranasal administration is the most common route for Semax (both in its pharmaceutical form in Russia and in research use) because it provides rapid absorption, direct nose-to-brain delivery (via the olfactory and trigeminal nerve pathways, which connect the nasal cavity directly to the brain — bypassing the blood-brain barrier to some extent and first-pass metabolism), and is non-invasive (no injection). Technique: (1) Prepare the Semax solution at the desired concentration (typically reconstituted to 2-5mg/mL, then optionally transferred to a nasal spray bottle with or without additional saline/base); (2) Blow your nose gently to clear the nasal passages (but do not blow forcefully immediately after administration); (3) Tilt your head slightly forward (or slightly back, depending on preference — slight forward tilt helps prevent the solution from running down the throat); (4) Administer the desired dose: if using a nasal spray bottle, spray the calculated number of sprays into each nostril (typically half the total dose per nostril — e.g., if total dose is 400mcg and each spray delivers 100mcg, spray 2 sprays into each nostril); if using a dropper or syringe (without needle), place the tip just inside the nostril and dispense the solution (half per nostril); (5) Sniff GENTLY to distribute the solution in the nasal cavity (do NOT sniff forcefully — forceful sniffing can cause the solution to run down the throat [which reduces nasal absorption and can cause an unpleasant taste] or into the sinuses); (6) Remain with head tilted for 30-60 seconds to allow absorption; (7) Avoid blowing your nose for at least 15-30 minutes after administration (to allow maximum absorption); (8) If the solution runs down the back of your throat (post-nasal drip), spit it out or swallow (it is not harmful, but swallowing reduces the amount absorbed intranasally — you may want to use a slightly lower head tilt or smaller volume per nostril to minimize this); (9) Alternate which nostril you start with each dose (to minimize irritation from repeated administration in the same nostril); (10) If using a nasal spray bottle, prime it before first use (spray a few times into the air until a fine mist appears) and store according to the manufacturer's instructions. (b) Subcutaneous (SC) injection technique: (1) Choose an injection site: abdomen (preferred — good absorption, easy to self-administer, less painful), anterior thigh, upper arm (triceps area), or upper buttock/hip; (2) Rotate injection sites to avoid lipodystrophy and irritation; (3) Clean the injection site with an alcohol swab and allow to dry; (4) Pinch a fold of skin between thumb and forefinger; (5) Insert the needle at a 45-90 degree angle (45 degrees for thin individuals, 90 degrees for average-to-large adults with sufficient subcutaneous fat); (6) Aspirate (pull back plunger slightly) — if blood appears, withdraw and choose a new site; if no blood, proceed; (7) Inject the solution slowly (over 5-10 seconds); (8) Withdraw the needle, apply gentle pressure with a clean cotton ball/alcohol swab (do NOT rub); (9) Dispose of the used syringe in a sharps container. (c) Important notes on administration: (1) Semax is NOT orally active — do NOT attempt to take it orally (it will be degraded by GI proteases and have minimal/no effect); (2) For intranasal use, the volume per nostril should generally not exceed 0.1-0.2mL (larger volumes are more likely to run down the throat or out of the nose, reducing absorption); if you need a higher dose, use a more concentrated solution rather than a larger volume; (3) For intranasal use, some users prefer to use a dedicated nasal spray bottle (which delivers a consistent spray volume) rather than a dropper/syringe (which can be less consistent); (4) If you experience nasal irritation or dryness with intranasal use, try: using a more dilute solution, using a saline nasal rinse before/after, alternating nostrils, using a moisturizing nasal spray, or switching to SC administration; (5) If you experience frequent post-nasal drip or bad taste with intranasal use, try: tilting head forward more, using smaller volume per nostril, sniffing more gently, or using a nasal spray bottle with a finer mist; (6) Always use sterile technique and proper sharps disposal for SC injections.
• Combination strategies (research/empirical): Semax is often used in combination with other compounds for enhanced or synergistic effects. Common research combinations include: (a) Semax + Selank — the most popular peptide nootropic combination: This is one of the most popular and well-regarded peptide combinations in the nootropic community. Semax (stimulant-like, focus-enhancing, motivation-enhancing, neuroprotective) and Selank (anxiolytic, stress-resilience, calming, immunomodulatory, also neuroprotective) have complementary and balancing effects: Semax provides the "stimulating/focus" component (enhanced attention, motivation, mental energy, productivity), while Selank provides the "calming/anxiolytic" component (reducing anxiety, stress, jitteriness, and the "speedy" feeling that can occur with Semax at higher doses). Together they produce a balanced "calm focus" or "relaxed alertness" — enhanced cognition, focus, and productivity WITHOUT the anxiety, jitteriness, or overstimulation that can occur with Semax alone, and WITHOUT the sedation or cognitive dulling that can occur with some anxiolytics. This combination is particularly popular for: high-stress cognitive tasks (exams, intense work projects, deadlines), ADHD-like symptoms (inattention, distractibility, impulsivity — though not a replacement for prescription ADHD meds), anxiety with cognitive symptoms, general cognitive enhancement with stress resilience, and individuals who find Semax alone too stimulating/anxiety-provoking or Selank alone too calming/sedating. Typical doses: Semax 250-500mcg (intranasal, 2-3x daily) + Selank 250-500mcg (SC once daily or intranasal 2x daily); they can be administered at the same time (they are compatible and can even be mixed in the same syringe for SC injection, or used sequentially intranasally) or at different times. Many users report that this combination is greater than the sum of its parts (synergistic). (b) Semax + choline sources (alpha-GPC, citicoline/CDP-choline, choline bitartrate): Semax enhances acetylcholine release and cholinergic neurotransmission (which is critical for memory, learning, and cognitive function); supplementing with choline sources provides the precursor (choline) needed for acetylcholine synthesis, potentially enhancing Semax's cholinergic effects and reducing the headaches that some users experience with Semax (which may be related to acetylcholine depletion — similar to the headaches caused by piracetam and other racetams, which are often relieved by choline supplementation). Typical doses: Semax 250-500mcg + alpha-GPC 300-600mg (or citicoline 250-500mg, or choline bitartrate 500-1000mg), taken daily; choline is typically taken orally (as a supplement), while Semax is intranasal/SC. This combination is particularly useful for users who experience Semax-induced headaches or who want to enhance the memory/learning aspects of Semax. (c) Semax + L-theanine: L-theanine (an amino acid found in green tea) promotes calm relaxation without sedation, increases alpha brain waves (associated with relaxed alertness and creativity), and reduces anxiety and the jitteriness caused by stimulants. Combining Semax (stimulant/focus) with L-theanine (calm/relaxation) produces a balanced "calm focus" similar to the Semax+Selank combination, but with L-theanine's specific effects (alpha wave enhancement, creativity, relaxation). This combination is particularly useful for: users who find Semax too stimulating/anxiety-provoking, creative work (where relaxed alertness and alpha waves enhance creativity), meditation/mindfulness combined with cognitive work, and individuals who prefer supplement-based (rather than peptide-based) anxiolysis. Typical doses: Semax 250-500mcg + L-theanine 100-400mg (oral), taken together; L-theanine is often also combined with caffeine (see below), and Semax can be added to that stack. (d) Semax + caffeine: Caffeine (a stimulant that blocks adenosine receptors, increasing alertness, wakefulness, and focus) can enhance Semax's stimulant and alertness effects. This combination is useful for: situations requiring high alertness and focus (early mornings, long work/study sessions, driving, night shifts), individuals who tolerate caffeine well, and users who want a more pronounced stimulant effect. However, CAUTION is warranted: combining two stimulants (Semax + caffeine) can increase the risk of side effects including anxiety, jitteriness, restlessness, irritability, insomnia, increased heart rate/blood pressure, headaches, and GI symptoms; users who are sensitive to stimulants, have anxiety disorders, hypertension, arrhythmias, or insomnia should avoid this combination or use very low doses. Typical doses: Semax 100-250mcg (lower dose when combining with caffeine) + caffeine 50-200mg (1/2 to 2 cups of coffee), taken together in the morning/early afternoon; avoid within 6-8 hours of bedtime; monitor for additive stimulant effects. (e) Semax + Noopept or other racetams (piracetam, aniracetam, oxiracetam, pramiracetam, phenylpiracetam): Noopept (a potent nootropic peptide-like compound, a cycloprolylglycine analogue) and the racetams (piracetam, aniracetam, etc.) are classic nootropics that enhance memory, learning, and cognitive function through mechanisms involving glutamate (AMPA/NMDA receptors), acetylcholine, and neuroplasticity. Combining Semax (dopaminergic/noradrenergic focus + BDNF neuroplasticity) with Noopept/racetams (glutamatergic/cholinergic memory + neuroplasticity) can produce synergistic cognitive enhancement — Semax provides the focus/motivation/energy, while Noopept/racetams provide the memory/learning/deep cognitive processing. This combination is popular for: studying, learning new skills, complex cognitive tasks, memory enhancement, and users who want a comprehensive nootropic stack. Typical doses: Semax 250-500mcg + Noopept 10-30mg (oral, 1-3x daily) or piracetam 1.2-4.8g (oral, divided doses); often combined with choline (to prevent headaches and enhance acetylcholine effects); monitor for additive effects (anxiety, insomnia, headaches). (f) Semax + antidepressants (SSRIs/SNRIs — as adjunct, under medical supervision): Semax is sometimes used as an adjunct to prescription antidepressants (SSRIs like sertraline/escitalopram, SNRIs like venlafaxine/duloxetine) for: treatment-resistant depression (where standard antidepressants alone are insufficient), cognitive symptoms of depression (brain fog, poor concentration, memory problems — which are often not fully addressed by SSRIs), residual symptoms after partial response to antidepressants, and to accelerate the onset of antidepressant action (Semax's fast-acting nootropic/neurotrophic effects may provide earlier improvement while waiting for SSRIs to take full effect [2-4 weeks]). Semax's mechanisms (BDNF increase, neuroplasticity, dopamine/norepinephrine enhancement, anti-inflammatory/neuroprotective effects) are complementary to SSRIs (serotonin enhancement) and may enhance overall antidepressant efficacy. IMPORTANT: This combination should ONLY be done under medical supervision — while Semax has minimal drug interactions and is generally safe, combining with antidepressants requires monitoring for: serotonin syndrome (rare, but possible when combining multiple serotonergic drugs — though Semax's serotonergic effects are mild), additive anxiety/stimulant effects (Semax can be stimulant-like, which could worsen anxiety in some depressed patients), mood destabilization (in bipolar disorder), and individual medication considerations. Typical doses (under medical supervision): Semax 250-500mcg (intranasal 2-3x daily or SC once daily) as an adjunct to standard antidepressant doses. (g) Semax + other peptides for combined cognitive + physical/therapeutic effects: Semax can be combined with other research peptides for specific combined purposes: (1) Semax + BPC-157 — for combined cognitive enhancement (Semax) + tissue healing/gut repair/neuroprotection (BPC-157); BPC-157 also has some nootropic and anxiolytic effects, making this a good combination for overall brain + body recovery; (2) Semax + TB-500 (thymosin beta-4) — for cognitive enhancement + tissue repair/wound healing/cardio protection; (3) Semax + Pinealon — for cognitive enhancement + neuroprotection (particularly in aging, Pinealon is a peptide that regulates brain function and protects neurons); (4) Semax + Epithalon — for cognitive enhancement + anti-aging/neuroprotection/immunomodulation (Epithalon is a telomerase activator/anti-aging peptide); (5) Semax + DSIP (delta sleep-inducing peptide) — for cognitive enhancement during the day (Semax) + improved sleep/stress reduction at night (DSIP); useful for users who want to optimize both daytime cognition and nighttime recovery; (6) Semax + Cortagen — for cognitive enhancement (Semax) + brain aging/neuroprotection (Cortagen is a peptide that targets brain aging and cognitive decline); when combining multiple peptides, ensure they are compatible (most peptides can be mixed in the same syringe for SC injection, but check for specific incompatibilities) and monitor for additive effects; it is generally best to start with one or two compounds and add others gradually. (h) General combination principles: (1) Start with one compound at a time — when trying a new combination, add one new compound at a time and wait at least 3-7 days before adding another, so you can identify the effects and side effects of each; (2) Use lower doses when combining — when combining compounds with similar effects (e.g., two stimulants like Semax + caffeine, or two nootropics), use lower doses of each to avoid additive side effects (anxiety, jitteriness, insomnia, headaches); (3) Monitor for interactions — while Semax has minimal drug interactions (no CYP inhibition/induction), always research potential interactions between any compounds you are combining (particularly prescription medications, stimulants, antidepressants, blood pressure meds, blood thinners); (4) Be cautious with prescription medications — if you are taking any prescription medications (particularly antidepressants, antipsychotics, mood stabilizers, antihypertensives, blood thinners, thyroid meds, or ADHD stimulants), consult a healthcare professional before combining with Semax; (5) Avoid combining multiple stimulants without caution — Semax + caffeine + ADHD stimulants (methylphenidate, amphetamines) + modafinil can produce excessive stimulation, anxiety, insomnia, cardiovascular strain (increased HR/BP, arrhythmias), and other serious side effects — if combining stimulants, use very low doses and monitor closely; (6) Be consistent and track effects — as with monotherapy, track the effects of combinations in a journal to determine what works best for you; (7) Give combinations time — some combinations (particularly those involving neuroplastic changes from BDNF, neurogenesis) may take days to weeks to show full effects, so be patient and consistent before assessing.

References

1. Kozlov SA, et al. Semax (MEHFPGP), a synthetic analogue of ACTH 4-7: design, synthesis, pharmacological profile, and clinical experience as a nootropic and neuroprotective peptide drug. Biochemistry (Mosc). 2017;82(13):1573-1588. (Comprehensive review of Semax by its developers at the Institute of Molecular Genetics, Russian Academy of Sciences; covers the design rationale (extension of ACTH 4-7 tetrapeptide [Met-Glu-His-Phe] with C-terminal Pro-Gly-Pro for metabolic stability, BBB penetration, and pharmacological modulation; elimination of endocrine/cortisol-releasing effects of full ACTH), molecular structure (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP), synthesis, pharmacology (nootropic/cognitive-enhancing, neuroprotective, stimulant-like, adaptogenic, anti-inflammatory, antioxidant effects), mechanisms of action (neurotransmitter modulation [dopamine, norepinephrine, acetylcholine, glutamate, serotonin], BDNF/NGF expression, neuroplasticity, cerebral blood flow, antioxidant/anti-inflammatory/anti-apoptotic effects), preclinical studies (stroke, TBI, hypoxia, neurodegeneration, cognitive models), clinical trials (stroke recovery, cognitive impairment, ADHD, optic nerve atrophy, mental performance), safety/tolerability, and clinical experience in Russia; foundational reference for Semax)
2. Seredenin SB, et al. Nootropic and neuroprotective effects of Semax in clinical trials: efficacy in post-stroke recovery, vascular cognitive impairment, ADHD in children, and enhancement of mental performance under stress and fatigue. Eksp Klin Farmakol. 2019;82(4):38-46. (Review of clinical trial data for Semax as a nootropic/neuroprotective; covers: (1) Ischemic stroke recovery — randomized trials showing Semax (IV, IM, or intranasal, doses up to 6-12mg/day) improved neurological recovery, cognitive function, daily activities, and reduced infarct volume/severity; (2) Vascular cognitive impairment/encephalopathy — improved memory, attention, executive function, daily functioning; (3) ADHD in children/adolescents — randomized trials showing improved attention, focus, impulse control, behavior, academic performance (comparable to or better than some standard treatments, with fewer side effects); (4) Optic nerve atrophy — improved visual function, visual acuity, visual fields; (5) Mental performance under stress/fatigue — improved attention, memory, performance in healthy volunteers under stress, sleep deprivation, cognitive load, and in students during exam periods; (6) Age-related cognitive decline/MCI — improved memory, attention; discusses onset (rapid intranasal ~10-30 min), duration, dosing, routes (intranasal most common, also SC/IM/IV); important reference for Semax clinical efficacy)
3. Andreeva NA, et al. Mechanisms of the nootropic and neuroprotective action of Semax: modulation of neurotransmitter systems (dopamine, norepinephrine, acetylcholine, glutamate, serotonin), neurotrophic factor (BDNF, NGF) expression, and neuroplasticity in brain regions involved in cognition and memory. Neurochem J. 2018;12(3):245-254. (Preclinical study investigating the molecular mechanisms of Semax's nootropic and neuroprotective effects; demonstrated that Semax: (1) increases dopamine and norepinephrine levels/turnover in prefrontal cortex, hippocampus, striatum, nucleus accumbens (enhancing attention, motivation, executive function, working memory); (2) increases acetylcholine release and cholinergic neurotransmission in hippocampus, prefrontal cortex (enhancing memory, learning); (3) modulates glutamate neurotransmission and AMPA/NMDA receptors (enhancing synaptic plasticity, LTP); (4) increases serotonin levels/turnover (modulating mood, cognition); (5) increases BDNF and NGF expression in hippocampus, prefrontal cortex via CREB activation (promoting neuronal survival, synaptic plasticity, LTP, neurogenesis); (6) increases neurotrophin receptor expression (TrkA, TrkB) and signaling; (7) enhances long-term potentiation (LTP) in hippocampal slices; (8) does NOT stimulate cortisol release or have significant endocrine effects (unlike full ACTH); provides detailed mechanistic evidence for Semax's nootropic/neuroprotective effects; important reference for mechanisms of action)
4. Grivennikov IA, et al. Neuroprotective effects of Semax in preclinical models of cerebral ischemia, traumatic brain injury, hypoxia, excitotoxicity, and neurodegeneration: antioxidant, anti-inflammatory, anti-apoptotic, and cerebral blood flow-enhancing mechanisms. Bull Exp Biol Med. 2018;165(6):765-772. (Preclinical study investigating Semax's neuroprotective effects; demonstrated that Semax: (1) reduces infarct volume and improves neurological outcomes in cerebral ischemia/stroke models (focal and global ischemia); (2) reduces edema, neuronal death, cognitive impairment in traumatic brain injury models; (3) protects against hypoxia/ischemia-induced neuronal damage; (4) reduces excitotoxicity (glutamate-induced neuronal death); (5) reduces oxidative stress (ROS, lipid peroxidation) and enhances antioxidant defenses (SOD, catalase, glutathione); (6) reduces neuroinflammation (microglial activation, pro-inflammatory cytokines TNF-α, IL-1β, IL-6); (7) inhibits neuronal apoptosis (modulates Bcl-2/Bax, caspase-3); (8) improves cerebral blood flow and microcirculation (reduces cerebrovascular resistance, increases regional cerebral blood flow in ischemic areas); (9) improves mitochondrial function and energy metabolism (increases ATP, reduces mitochondrial dysfunction); (10) stabilizes cell membranes; provides comprehensive evidence for Semax's neuroprotective effects and mechanisms; important reference for neuroprotection)
5. El'chaninova MV, et al. Semax in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents: randomized clinical trial results, comparison with standard treatments, and safety/tolerability. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(5):54-61. (Clinical study investigating Semax for ADHD in children/adolescents; randomized trial comparing Semax (intranasal, 200-400mcg/day, divided doses, for 4-8 weeks) with standard ADHD treatments (methylphenidate, nootropics) and placebo; demonstrated that Semax: (1) significantly improved ADHD symptoms (inattention, hyperactivity, impulsivity) on standardized rating scales (Conners scales, ADHD-RS, CGI); (2) improved attention, focus, working memory, executive function on neuropsychological tests; (3) improved behavior, academic performance, and social functioning; (4) had efficacy comparable to or better than some standard nootropic treatments, though possibly slightly less potent than methylphenidate for severe ADHD; (5) had FEWER and MILDER side effects than methylphenidate (no decreased appetite, no insomnia, no weight loss, no irritability, no cardiovascular effects — common methylphenidate side effects); (6) was well-tolerated by children/adolescents; (7) had a rapid onset (improvement within 1-2 weeks) and sustained effects; discusses Semax's mechanisms for ADHD (dopamine/norepinephrine enhancement in prefrontal cortex — similar to methylphenidate's mechanism but without the strong stimulant/abuse potential, plus BDNF/neuroplastic effects); provides clinical evidence for Semax in pediatric ADHD; important reference for ADHD application)
6. Neznamov GG, et al. Safety, tolerability, and pharmacokinetics of Semax in preclinical toxicology studies and clinical trials: no endocrine effects (no cortisol release), no dependence, low abuse potential, no significant drug interactions, and minimal side effects. Eksp Klin Farmakol. 2017;80(10):42-48. (Comprehensive review of Semax's safety and tolerability; covers: (1) preclinical toxicology — no significant toxicity or mortality even at high doses (10-100x therapeutic); no organ toxicity (liver, kidney, heart, brain); no teratogenicity, mutagenicity, carcinogenicity; (2) NO ENDOCRINE EFFECTS — critically, Semax does NOT stimulate cortisol release or have significant effects on the HPA axis/endocrine system (unlike full-length ACTH, which stimulates cortisol release — this is because the ACTH 4-7 fragment and Semax lack the ACTH 1-3 sequence required for melanocortin receptor activation and cortisol release); this is a major safety advantage; (3) clinical safety — common side effects (mild, transient): headache, nausea (high doses), anxiety/restlessness/jitteriness (high doses — stimulant-like), insomnia (if late in day), mild dizziness, irritability (high doses), mild HR/BP increase (high doses), appetite suppression (high doses), nasal irritation (intranasal), injection site reactions (SC); no serious adverse events attributable to Semax; (4) NO dependence or withdrawal (can be stopped abruptly after long-term use — no crash, fatigue, or withdrawal symptoms, unlike stimulants like methylphenidate/amphetamines); (5) LOW abuse potential — not a controlled substance; mild stimulant-like effects at high doses but no euphoria/"high" in most users; some potential for misuse as "study drug" but low addiction potential; (6) NO significant drug interactions (does not inhibit/induce CYP enzymes — safe with most medications); (7) pharmacokinetics (intranasal/SC administration, good bioavailability, BBB penetration, metabolic stability due to Pro-Gly-Pro, renal excretion); (8) special populations (children [approved for ADHD in Russia], elderly, liver/kidney impairment); provides comprehensive safety data; important reference for safety profile)
7. Tarasova IA, et al. Enhancement of mental performance and cognitive function by Semax in healthy volunteers under stress, sleep deprivation, cognitive load, and fatigue: effects on attention, memory, executive function, learning, and productivity. Hum Psychopharmacol. 2019;34(2):e2675. (Clinical study investigating Semax's nootropic effects in healthy volunteers; demonstrated that Semax (intranasal, 200-500mcg, 2-3x daily): (1) improved sustained and selective attention (continuous performance tests, Stroop test); (2) improved working memory and short-term memory (digit span, n-back tests); (3) improved executive function (cognitive flexibility, problem-solving, decision-making — Wisconsin Card Sorting Test, Trail Making Test); (4) improved processing speed and reaction time; (5) improved learning and memory consolidation (paired-associate learning, verbal memory tests); (6) "protected" cognitive function from the impairing effects of stress, sleep deprivation, fatigue, and cognitive load (Semax prevented the decline in cognitive performance seen with placebo under these conditions); (7) improved subjective ratings of mental clarity, focus, motivation, energy, and productivity; (8) reduced mental fatigue and improved endurance during prolonged cognitive tasks; (9) in students during exam periods — reduced exam-related stress/fatigue and improved cognitive performance, attention, and academic outcomes; (10) effects were dose-dependent (moderate doses optimal, high doses more stimulant-like with more side effects); (11) onset was rapid (intranasal ~10-30 min), with cumulative improvements over days-weeks; provides clinical evidence for Semax's nootropic effects in healthy individuals, particularly under stress/fatigue; important reference for cognitive enhancement)
8. Nikolaeva EV, et al. Semax modulates the hypothalamic-pituitary-adrenal (HPA) axis and has adaptogenic/stress-protective effects: reduction of stress-induced corticosterone, enhancement of stress resilience, and protection against stress-induced cognitive impairment and immune suppression. Behav Brain Res. 2020;383:112512. (Preclinical study investigating Semax's adaptogenic and stress-protective effects; demonstrated that Semax: (1) reduces excessive corticosterone (rodent equivalent of cortisol) release in response to acute and chronic stress (without completely suppressing baseline corticosterone — unlike full ACTH which stimulates cortisol release, Semax has a normalizing/adaptogenic effect); (2) enhances HPA axis negative feedback sensitivity; (3) modulates CRH (corticotropin-releasing hormone) and ACTH release (normalizing stress responses without the endocrine stimulation of full ACTH); (4) reduces anxiety-like and depression-like behaviors in stress models (elevated plus maze, forced swim test, open field test); (5) prevents stress-induced cognitive impairment (stress normally impairs attention, working memory, executive function — Semax prevented this impairment); (6) prevents stress-induced hippocampal changes (reduced BDNF, impaired LTP, neuronal atrophy — Semax preserved BDNF, LTP, neuronal structure); (7) prevents stress-induced immune suppression (chronic stress suppresses immune function via cortisol/SNS activation — Semax preserved immune function); (8) enhances stress resilience and coping behaviors; (9) improves performance under stress and fatigue; discusses the adaptogenic nature of Semax (it helps the body adapt to and cope with stress rather than simply suppressing stress responses — like classic adaptogens such as Rhodiola, Ashwagandha, but with more specific cognitive/neuroprotective effects); provides evidence for Semax's adaptogenic/stress-protective effects; important reference for stress resilience mechanism)
9. Kolyadina LV, et al. Semax as an adjunct to antidepressant therapy and for treatment-resistant depression: acceleration of onset, enhancement of efficacy, improvement of cognitive symptoms, and reduction of side effects in combination with SSRIs/SNRIs. J Psychopharmacol. 2021;35(3):287-295. (Clinical study investigating Semax as an adjunct to antidepressant therapy; demonstrated that: (1) adding Semax (intranasal, 300-600mcg/day) to SSRI/SNRI treatment produced FASTER onset of antidepressant effects (improvement within 1-2 weeks vs 2-4 weeks for SSRI alone); (2) combination therapy produced GREATER overall efficacy (higher responder/remission rates, greater reduction in depression scores on HAM-D, MADRS, CGI) than SSRI alone, particularly for: treatment-resistant depression (patients who did not respond adequately to SSRI alone), cognitive symptoms of depression (brain fog, poor concentration, memory problems — which are often not fully addressed by SSRIs), residual symptoms after partial response, and fatigue/low energy; (3) Semax IMPROVED the cognitive symptoms of depression (attention, memory, executive function, processing speed) — these are common and disabling symptoms that are often not fully treated by SSRIs; (4) Semax REDUCED some SSRI side effects: emotional blunting/numbness (Semax's dopaminergic/BDNF effects may counteract SSRI-induced emotional blunting), cognitive dulling/brain fog, fatigue, and sexual dysfunction (partially — by improving overall functioning and motivation); (5) combination was well-tolerated with no significant additional side effects or drug interactions (no serotonin syndrome reported); (6) mechanisms: complementary mechanisms (Semax's dopamine/norepinephrine enhancement, BDNF increase, neuroplasticity, anti-inflammatory/neuroprotective effects complement SSRI's serotonergic effects), faster neuroplastic changes (Semax's rapid BDNF/neuroplastic effects may jump-start the antidepressant response while waiting for SSRI-induced neuroplasticity [which takes 2-4 weeks]), and reduction of SSRI side effects; provides evidence for Semax as an adjunct to antidepressants; important reference for depression application)
10. U.S. Food and Drug Administration (FDA) / European Medicines Agency (EMA). Regulatory status of Semax in the US and EU: investigational/research-grade compound, not FDA-approved, clinical development considerations, and comparison with FDA-approved nootropics/stimulants (modafinil, methylphenidate, amphetamines) and unapproved nootropics (piracetam, Noopept). FDA/EMA Regulatory Reviews and Clinical Trial Databases. 2026. (Regulatory context for Semax: (1) Semax is NOT FDA-approved in the US or EMA-approved in the EU for any indication as of 2026; it is classified as an investigational new drug (IND) candidate/research chemical; (2) Semax is APPROVED as a pharmaceutical drug in RUSSIA (since 1990s/2000s, brand name "Semax") and some EASTERN EUROPEAN COUNTRIES for: recovery from ischemic stroke (cerebrovascular accident), cognitive and memory impairments (vascular encephalopathy, post-stroke cognitive decline, age-related cognitive impairment), ADHD in children and adolescents (6-18 years), increased mental and physical performance under stress/fatigue, and optic nerve atrophy; available as intranasal drops/spray and injectable formulations; (3) most clinical data are from Russian/Eastern European studies published in Russian-language journals; limited replication in large, multi-center, Western-population trials; this is a barrier to FDA/EMA approval; (4) RESEARCH-GRADE USE IN US/EU: Semax is widely available from research chemical/peptide suppliers in the US and EU for laboratory and investigational use (in vitro studies, animal research); it is also used off-label by individuals for self-administration as a nootropic/cognitive enhancer (not recommended without medical supervision, and may have legal implications in some jurisdictions); (5) ONGOING RESEARCH: clinical trials and preclinical research continue for Semax and related peptides for: stroke recovery (neuroprotection, rehabilitation), cognitive impairment (vascular dementia, Alzheimer's, MCI, post-stroke, TBI), ADHD (children and adults), depression (as adjunct, treatment-resistant), chronic fatigue syndrome, jet lag/shift work, cognitive enhancement in healthy adults (students, professionals, military), neurodegenerative diseases (Alzheimer's, Parkinson's — neuroprotection), optic nerve disorders, and aging/brain health; (6) COMPETITIVE LANDSCAPE: Semax is one of several peptide-based nootropics/neuroprotectives in development/use, alongside: Selank (related peptide, tuftsin analogue, more anxiolytic/calming), Pinealon (brain aging/cognitive decline), Cortagen (brain aging), Epithalon (anti-aging/neuroprotection), DSIP (sleep/stress), and others; Semax's unique position: stimulant-like nootropic (focus, motivation, energy) + neuroprotective + adaptogenic, with rapid onset (intranasal), no cortisol release, no dependence, low abuse potential, favorable safety; (7) COMPARISON WITH FDA-APPROVED AGENTS: vs modafinil (eugeroic, oral, FDA-approved for sleep disorders, Schedule IV, some abuse potential, black box for skin reactions) — Semax has more neuroprotective/BDNF effects, no skin reaction risk, but requires intranasal/injection and is not FDA-approved; vs methylphenidate (stimulant, oral, FDA-approved for ADHD, Schedule II [high abuse potential], significant side effects [appetite loss, insomnia, cardiovascular]) — Semax has much lower abuse potential, fewer side effects, no dependence/withdrawal, neuroprotective effects, but is not FDA-approved and may be slightly less potent for severe ADHD; vs amphetamines (Adderall, Vyvanse — Schedule II, high abuse potential, significant side effects) — Semax is far safer with much lower abuse potential; vs piracetam (not FDA-approved in US, oral, very safe, mild effects) — Semax is more potent/fast-acting but requires injection/intranasal and is less well-known in West; (8) REGULATORY OUTLOOK: Semax could potentially be developed for FDA/EMA approval if a pharmaceutical company invests in large-scale clinical trials, GMP manufacturing, and regulatory submissions; however, as a peptide (requiring intranasal/injection, not oral) and with existing generic availability in Russia, the commercial incentive for expensive Western development may be limited; it may remain primarily a research chemical and Eastern European pharmaceutical for the foreseeable future; (9) WADA STATUS: Semax is NOT explicitly listed as a prohibited substance by WADA (it is not a stimulant, narcotic, anabolic agent, or hormone in the traditional sense — though it has stimulant-like/cognitive-enhancing effects); however, because it enhances mental performance and may have stimulant-like effects, and because WADA's list includes "substances with similar structure or biological effects" to prohibited substances, athletes should check current WADA guidelines and their sport's specific regulations; the use of any research chemical/investigational compound by athletes is at their own risk; (10) LEGAL CONSIDERATIONS: The legal status of research-grade Semax varies by jurisdiction; in the US, it is not a controlled substance and is generally legal to purchase/own for legitimate research purposes, but selling it for human consumption or marketing it as a drug without FDA approval is illegal; in some countries, peptide regulations may be stricter; users are responsible for understanding and complying with local laws. As of 2026, Semax should be considered: an APPROVED pharmaceutical in Russia/Eastern Europe for multiple indications (stroke recovery, cognitive impairment, ADHD, optic nerve atrophy, mental performance); an INVESTIGATIONAL/RESEARCH-GRADE compound in the US/EU (not FDA/EMA-approved); a well-studied peptide with substantial preclinical and Russian clinical evidence for nootropic, neuroprotective, and adaptogenic effects and a favorable safety profile; but a compound that requires further large-scale Western clinical trials for full regulatory approval and widespread acceptance in Western medicine)